Exozymes (EXOZ) Change in Receivables (2023 - 2025)
Exozymes (EXOZ) posted quarterly Change in Receivables of $214716.0 for Q4 2025, up 17.13% year-over-year from $183319.0 in Q4 2024, and up 374.66% quarter-over-quarter from $45236.0 in Q3 2025.
Exozymes (EXOZ) Change in Receivables (2023 - 2025) Analysis & Trends
Exozymes (EXOZ) has reported Change in Receivables for 3 consecutive years, with $214716.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Receivables rose 17.13% year-over-year to $214716.0; the TTM figure through Dec 2025 stood at -$219923.0 (down 51.63% YoY), while the FY2025 annual figure was -$219923.0, down 51.63% from the prior year.
- Change in Receivables rose to $214716.0 in Q4 2025 per EXOZ's latest filing, from $45236.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $229292.0 in Q1 2024 and bottomed at -$593208.0 in Q3 2024.
- Historically, Change in Receivables has averaged -$17677.0 across 3 years, with a median of $45236.0 in 2025.
- On a YoY basis, Change in Receivables climbed as much as 107.63% in 2025 and fell as far as 1049.81% in 2025.
- Exozymes' Change in Receivables stood at $205867.0 in 2023, then decreased by 10.95% to $183319.0 in 2024, then rose by 17.13% to $214716.0 in 2025.
- Business Quant data shows EXOZ's Change in Receivables at $214716.0 in Q4 2025, $45236.0 in Q3 2025, and -$337753.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 214,716.00 |
| Dec 31, 2025 | 214,716.00 |
| Sep 30, 2025 | 45,236.00 |
| Sep 30, 2025 | 45,236.00 |
| Jun 30, 2025 | -337,753.00 |
| Jun 30, 2025 | -337,753.00 |
| Mar 31, 2025 | -142,122.00 |
| Mar 31, 2025 | -142,122.00 |
| Dec 31, 2024 | 183,319.00 |
| Dec 31, 2024 | 183,319.00 |
| Sep 30, 2024 | -593,208.00 |
| Sep 30, 2024 | -593,208.00 |
| Jun 30, 2024 | 35,560.00 |
| Jun 30, 2024 | 35,560.00 |
| Mar 31, 2024 | 229,292.00 |
| Mar 31, 2024 | 229,292.00 |
| Dec 31, 2023 | 205,867.00 |
| Dec 31, 2023 | 205,867.00 |